CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Neurocrine Biosciences, Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Neurocrine Biosciences, Inc
6027 EDGEWOOD BEND COURT
Phone: (858) 617-7600p:858 617-7600 SAN DIEGO, CA  92130  United States Ticker: NBIXNBIX
This company was Merged or Acquired on 1/8/2026.
This is a Subsidiary, click here for the Parent Company
Business Summary
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator? / (AMPA PAM) and others.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
8071 Medical laboratories

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board William H.Rastetter 77 5/1/2011 2/8/2010
President, Chief Executive Officer, Director Kyle W.Gano 53 10/11/2024 1/1/2011
Chief Financial Officer Matthew C.Abernethy 46 11/29/2017 11/29/2017
12 additional Officers and Directors records available in full report.

Business Names
Business Name
Diurnal Group PLC
NBIX
Neurocrine Continental, Inc.
6 additional Business Names available in full report.

General Information
Number of Employees: 2,000 (As of 3/31/2026)
Outstanding Shares: 100,549,983 (As of 4/28/2026)
Shareholders: 35
Stock Exchange: NASD
Federal Tax Id: 330525145
Fax Number: (302) 636-5454
Email Address: ir@neurocrine.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, May 30, 2026